Phenotypes Associated with This Genotype

Genotype
MGI:5486065

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Sftpc^{tm1.1(cre/ERT2)Ptch}/Sftpc⁺; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased tumor-free survival time ( J:195738 )

• many mice do not survive to 13 weeks after tamoxifen treatment due to high tumor burden

• mice display leaky cre expression without tamoxifen treatment and survive a few months longer than tamoxifen-treated animals

neoplasm

increased lung adenoma incidence ( J:195738 )

• after tamoxifen treatment, mice show a more severe phenotype than animals with wild-type Trp53 (greater tumor size, tumor growth and tumor grade); by 3-4 weeks after tamoxifen treatment, several small adenomas of papillary nature are observed in alveoli

• at 10 weeks after tamoxifen injection, many alveoli have large tumors; tumors exhibit enlarged pleomorphic nuclei, aberrant mitosis; tumor giant cells are present

increased lung adenocarcinoma incidence ( J:195738 )

• mice surviving to 13 weeks after tamoxifen treatment have adenocarcinomas in the alveoli of the lungs

• without tamoxifen treatment, mice develop invasive lung adenocarcinomas localized to the alveoli

• bronchioalveolar duct junctions (BADJs) appear normal ( in mice with or without tamoxifen treatment)

respiratory system

increased lung adenoma incidence ( J:195738 )

• after tamoxifen treatment, mice show a more severe phenotype than animals with wild-type Trp53 (greater tumor size, tumor growth and tumor grade); by 3-4 weeks after tamoxifen treatment, several small adenomas of papillary nature are observed in alveoli

• at 10 weeks after tamoxifen injection, many alveoli have large tumors; tumors exhibit enlarged pleomorphic nuclei, aberrant mitosis; tumor giant cells are present

increased lung adenocarcinoma incidence ( J:195738 )

• mice surviving to 13 weeks after tamoxifen treatment have adenocarcinomas in the alveoli of the lungs

• without tamoxifen treatment, mice develop invasive lung adenocarcinomas localized to the alveoli

• bronchioalveolar duct junctions (BADJs) appear normal ( in mice with or without tamoxifen treatment)

increased type II pneumocyte number ( J:195738 )

• 8 days after tamoxifen treatment, extensive type II cell proliferation is observed compared to wild-type; however, proliferating bronchioalveolar stem cells (BASCs) are rarely observed (at 8 days, 3, 6, 10 and 13 weeks after tamoxifen treatment)

• tumor cells express type II cell markers and are highly proliferative, even without tamoxifen treatment